and serum eosinophil cationic protein levels (17.6 vs 16.1 ng/ml; range, 6.3 to 17.5 vs 6.3 to 60.3 ng/ml; p ---0.03) at 16.'00 hours were detected compared with group 2. Conclusions: Our findings suggest that increased NAN is more likely to occur in subjects with asthma with ongoing increased cellular activation during the day. (J ALLERGY CLIN 1MMUNOL 1995,'96:219-29.) 
blood (PB) eosinophil numbers and their activation parameters during the night in subjects with nocturnal asthma have been found to be either increased 5, 6 or decreased, y and conflicting results have been reported as to PB histamine levels as well. y, g From the various studies it can often not be deduced whether the circadian variations are due to pathologic processes underlying nocturnal asthma or whether they belong to normal physiologic circadian rhythms. For instance, both in normal and asthmatic subjects circadian rhythms exist in PB leukocyte number and their functional activity. 9 Similar chronobiologic rhythms in cell number and activity in the airways can be postulated. So far, however, circadian variations in inflammatory cells in BAL fluid of healthy persons have scarcely been investigated.
The aim of this study was to investigate the presence of inflammatory cells and mediators in BAL fluid and PB at 16:00 and 04:00 hours from healthy subjects and from atopic patients with asthma and to determine their relationship with the occurrence of increased NAN in asthma, as assessed by measurement of the circadian peak expiratory flow (PEF) rhythm. Eosinophils and mast cells are considered as principal effector cells?0, n Their activation parameters, as assessed by EG2+-staining cells, eosinophil cationic protein (ECP), eosinophil-derived neurotoxin (EDN), histamine, and prostanoids, have been found to be increased in the BAL fluid of patients with stable and symptomatic asthma? 246 These cell types and activation parameters were assessed in BAL fluid, whereas in PB eosinophil numbers and ECP levels were determined.
METHODS Subjects
Eight healthy subjects and 17 subjects with asthma (age range, 18 to 45 years) participated in the study (Table I ). The subjects were recruited through advertisements in local newspapers and from the outpatient clinic of our hospital. The study was approved by the ethical committee of the hospital, and written informed consent was given by each subject.
At entry to the study the selected healthy volunteers had no history of lung disease or allergy; no atopy, as demonstrated by negative results of intracutaneous tests against 18 common aeroallergens, expressed as histamine equivalent wheal size less than 0.7 (Diephuis Laboratories, Groningen, The Netherlands); no airway response on provocation with methacholine, as determined by a fall in forced expiratory volume in 1 second (FEV1) of less than 10% after inhalation of methacholine bromide in a concentration of 9.8 mg/ml (2-minute inhalation, 5-minute interval); and no upper respiratory infections within 1 month before the study and no concomitant diseases.
Subjects with asthma were prospectively selected on the basis of a history of episodic dyspnea or wheezing consistent with the clinical diagnosis of asthma17; atopy, as determined by positive results of intracutaneous tests against house dust mite or two of 18 other tested common aeroallergens (histamine equivalent wheal size ->0.7); FEV1 greater than 1.50 L and 70% or more of predicted value; postbronchodilator FEV1 (400 Ixg salbutamol with a spacehaler) 80% or more of predicted value; airway hyperresponsiveness to methacholine, defined as the provocative concentration of methacholine bromide that caused a 20% fall in FEV1 (PC2o) of 9.8 mg/ml or less (2-minute inhalation, 5-minute interval); no use of oral corticosteroids within 2 months before the study; no upper respiratory infections within 1 month before the study and no other concomitant diseases.
Study design
In the subjects with asthma inhaled corticosteroids and cromolyns were stopped 4 weeks before the start of the study. Until the last bronchoscopy subjects were allowed to use inhaled bronchodilators only ([32-agonists or ipratropium bromide).
The week before the study PEF values were recorded for 3 days at 08:00, 12:00, 16:00, 20:00, 24:00, and 4:00 hours. Bronchodilators were withheld. The best of three PEF maneuvers was recorded. The mean circadian PEF variation of the 3 days was defined as (Highest 24 Hour Value -Lowest 24-Hour Value) + Mean 24-Hour Value. Subjects were prospectively selected in three groups: group 1 consisted of healthy volunteers, whereas subjects with asthma were assigned to group 2 if the mean circadian PEF variation was less than 15% and to group 3 if the PEF variation was 15% or greater. Nocturnal asthma symptoms were scored on the basis of nocturnal awakening caused by nocturnal dyspnea in the last week, as follows: 0 = never, 1 = sometimes, 2 = every night. FEV 1 and airway hyperresponsiveness to methacholine were assessed within 5 days before the first bronchoscopy.
Thirty minutes before each bronchoscopy, FEV 1 measurements were performed and PB samples were taken. Subjects rested for 15 minutes before the daytime lung function measurements. At night subjects were admitted to the hospital at 22:00 hours and were awakened 15 minutes before the measurements. Bronchodilator therapy was withheld 8 hours before the pulmonary function tests. Bronchoscopy was performed at 16:00 hours (4:00 PM) and 04:00 hours (4:00 AM) on two different days, separated by at least 7 days. Nineteen subjects underwent their first bronchoscopy at 16:00 hours, and five at 04:00 hours.
Pulmonary function and inhalation provocation tests
PEF values were recorded with a Wright mini peak flow meter. FEVa was measured with a calibrated watersealed spirometer according to standardized guidelines, 18 with the best of three measurements being used for analysis. Airway responsiveness to methacholine was measured by a 2-minute tidal breathing method. 19 Provocative concentration of a stimulus that causes a 20% decrease in FEV 1 (PC2o) were calculated by linear interpolation of the last two points of the log concentration response curve.
Bronchoscopy procedure
Fiber-optic bronchoscopy was undertaken according to guidelines described by the American Thoracic Society. 2° Premedication consisted of intramuscular injec-tion of 0.5 mg atropine and inhalation of 200 p~g salbutamol via a Volumatic spacer device (Glaxo, Utrecht, The Netherlands). Lidocaine 4% was applied as local anesthetic into the upper airways and bronchial tree. Supplementary oxygen was available. Bronchoscopy was performed with an Olympus B1 IT10 flexible fiber-optic bronchoscope (Olympus Optical Co., Tokyo, Japan). The instrument was inserted through the mouth and wedged in the lateral segment of the right middle lobe. Subsequently, 10 aliquots of 20 ml sterile phosphate-buffered saline solution (PBS) of 37 ° C were instilled and recovered by gentle suction (-40 cm H20 ) after each aliquot. The BAL fluid was collected in polypropylene tubes, which were immediately placed in ice.
Laboratory techniques
The BAL fluid was pooled in two fractions: pool 1 consisted of the fluid recovered from the first two 20 ml quantities of PBS instilled, which contained constituents from the proximal airways; pool 2 comprised the fluid from the remaining 8 quantities of 20 ml. Cell numbers and activation parameters were assessed in the first fraction. Because of a limited amount of BAL fluid in this fraction, the eicosanoids had to be determined in pool 2. The lavage fluid was filtered through a 100 ixm pore filter of a venous infusion system (Curapharm, Medica B.V., Hospital Supplies, Hertogenbosch, The Netherlands) to remove mucus and centrifuged at 400 g at 4 ° C for 5 minutes. The BAL supernatant was stored at -80°C until further determination. The cell pellets were resuspended in 1 ml PBS with 0.5% heat-inactivated bovine serum albumin (BSA) (PBS/BSA 0.5%).
Total leukocyte counts in PB and BAL cell suspensions were measured in a Coulter Counter (model S-plus VI; Coulter Electronics, Hialeah, Fla.), and viability was assessed by cellular exclusion of trypan blue. Cytocentrifuged preparations of both pools of BAL fluid were made from 100 Ixl fractions of the BAL cell suspension, diluted to a volume of 0.25 × 106 cells/ml in PBS/BSA, 0.5%, with a Shandon Cytospin-2 centrifuge (Shandon Inc., Pittsburgh, Pa.). After preparations were stained with May-Grtinwald-Giemsa, the average of 300 cell counts on two slides was taken as the differential cell count. Additional cytocentrifuged preparations were sealed in plastic and stored at -80 ° C for future staining and analysis. PB eosinophil numbers were counted in a Bfirker chamber after staining with eosin.
Activated eosinophils in the BAL fluid were identified by immunostaining of acetone-fixed cytocentrifuge preparations with the monoclonal antibody EG2 (Sanbio, Uden, The Netherlands), which detects a cleaved part of the ECP. A two-step alkaline phosphatase procedure was performed, according to the method described by Tai et al., 21 with minor modifications. The slides were incubated with 50 ixl EG2 solution (1:50) for 60 minutes. As a control for false-positive counting, the primary antibody was omitted or an irrelevant antibody was used as a first step. The slides were then incubated for 30 minutes with an alkaline phosphatase-conjugated rabbit anti-mouse IgG antibody (1:40) (Sigma, St. Louis, Mo.) supplemented with 5% human AB serum, followed by an alkaline phosphatase-conjugated goat anti-rabbit IgG antibody (1:40) supplemented with 5% human AB serum. The phosphatase reactivity was demonstrated by Fast Red (Sigma) (1 mg/ml) in tris(hydroxymethyl) aminomethene-HC1 buffer, 0.1 mol/L pH 8.2; containing 0.2 mg/ml naphthol AS-MX (Sigma) with 2 mmol/L levamisole (Sigma) to inhibit endogenous alkaline phosphatase. The slides were counterstained with fresh Mayers' hematoxylin. EG2 + cell counts were performed on two slides and the average counts of 500 cells on each slide was taken as the definitive number of positive cells. Only intact and unclustered cells were counted. Total EG2 + cell counts were calculated from the total leukocyte number per milliliter of BAL fluid.
ECP and EDN determination in serum and BAL fluid. Serum was obtained after coagulation of the blood for 1 hour at room temperature. The supernatant was centrifuged twice for 10 minutes at 2000 g and stored at -80°C until analysis. ECP was measured in serum, whereas ECP and EDN were determined in unprocessed BAL supernatants from pool 1. This was performed by double-antibody radioimmunoassays (RIA) (Pharmacia Diagnostics AB, Uppsala, Sweden), as described previously. 22,23 The detection level in both assays was 0.1 ng/ml.
Histamine determination in BilL fluid. Histamine was determined in unprocessed lavage supernatants from pool 1, with the RIA procedure from Immunotech (Westbrook, Maine), in accordance with the manufacturer's protocol.
Eicosanoid determination. Immediately after the BAL procedure 20 ml of BAL supernatant from pool 2 was processed on C18 SepPak cartridges (Millipore, Bedford, Mass.) as described previously, 24 eluted with 2.5 ml methanol and stored at -80 ° C until analysis. Samples of 200 ~xl eluted fluid were pipetted into polypropylene tubes and dried with a Savant sample concentrator. After dissolving in 300 txl assay buffer, thromboxane B 2 (TxB2) level was determined by means of a [3HI RIA with antisera from Advanced Magnetics Inc. (Cambridge, Mass.) and tritium-labeled compounds from Amersham International plc. (Amersham, Buckinghamshire, U.K.; prostaglandin (PG) D 2 and PGF2~ were tritium-labeled kits obtained from Amersham UK. 24 6-Keto PGFI~ (6kPGFa~) was determined by means of a iodine 125-labeled RIA kit (Du Pont de Nemours, Dreieich, Germany). Leukotriene C4/D4/E 4 was measured at room temperature in a microtiter enzyme immunoassay according to protocol (Biotrak, Amersham, UK). Crossreactivities for each assay to related compounds were negligible or less than 2% at B/Bo 50%.
Data analysis
PC2o values were analyzed after base 2 logarithmic transformation and expressed as the geometric mean VOLUME 96, NUMBER 2 PC2o value. After verification of the normal distribution, changes in values of lung function parameters within subjects were analyzed with the Student paired twotailed t test and between groups with the Student t test for unpaired observations. Nonparametric tests were used to analyze the cell number and activation parameters, the number of positive skin test results, and nocturnal asthma score. The Mann-Whitney U test was used to compare data between groups, and Wilcoxon's matched[ signed-rank test was applied for within-group analyses. Correlations between the circadian PEF variations, and lung function or cell parameters, were made by Spearman's rank correlation tests. All analyses were performed with the SPSS/PC ÷ V 4.01 software package (SPSS Inc., Chicago, ILL). Values ofp 0.05 or less were considered statistically significant.
RESULTS Subjects
Subject characteristics are listed in Table I . Group 1 consisted of healthy volunteers. Seven subjects with asthma were assigned to group 2 (mean circadian PEF variation, <15%) and 10 to group 3 (mean circadian PEF variation, >-15%). Mean circadian PEF rhythms in the control group and group 2 were not significantly different from each other. Age and gender were not significantly different among the three groups, nor were the number of positive skin test results and mean percentage of predicted FEV, between the two asthma groups. Mean percentage of predicted FEV 1 was significantly lower in both asthma groups as compared with the healthy control group (p < 0.05).
Subjects with asthma in group 3 scored significantly higher on awakening because of nocturnal dyspnea. (p = 0.03), and their geometric mean PC20 from methacholine was significantly lower as compared with the subjects with asthma in group 2 (0.26 and 0.9:1 mg/ml, respectively; p = 0.02). The circadian PEF variation of all subjects with asthma was significantly correlated with the PC20 methacholine values (r = -0.65, p = 0.007) and with the nocturnal asthma symptom score (r = 0.73, p = 0.009).
FEV., measurements
Mean FEV~ in group 3 decreased significantly at night as compared with the 16:00 hour value (from 87.5% + 13.7% to 75.7% + 19.2%, p = 0.005), whereas this was less pronounced in group 2 (from 92.6% :_~ 9.2% to 88.1% + 10.1%,p = 0.09). In the healthy control group no differences were foundbetween the 16:00 and 04:00 hour values (105% _+ 14.2% and 105% _+ 13.2%, respectively).
Bronchoscopy procedure
Results of BAL parameters in group 3 are based on data from nine subjects (subject 4 in this group refused a second bronchoscopy).
BAL cell analysis
The volume of fluid recovered, and total and differential cell numbers, in pool 1 are shown in Table II . The volume of fluid recovered was lower in the asthmatic groups than in the normal volunteers, but this reached significance only at 04:00 hours (p = 0.04). Mean total and differential cell numbers per milliliter of BAL fluid were not significantly different among the various groups at the different time points.
Eosinophil numbers were higher in the subjects with asthma as compared with the control group (16:00 hours, p --0.004; 04:00 hours, p = 0.05) but were not significantly different between the two asthmatic groups. In groups 1 and 2 the numbers tended to increase at night and ran parallel with increased numbers of neutrophils at 04:00 hours (p = 0.02 and p = 0.03, respectively).
EG2 + cell numbers showed the same pattern as the eosinophil numbers (Table II) . The numbers were significantly higher in the subjects with asthma than in the control subjects at 16:00 hours (p < 0.001), with the same trend at 04:00 hours. No statistical difference was found between both asthmatic groups. The numbers of EG2 + cells were always higher at 04:00 hours than at 16:00 hours and reached significance in group 2 (p = 0.04).
BAL inflammatory mediator levels
In all subjects with asthma EDN and histamine values were higher than in the control group and reached significance at 16:00 hours (p = 0.04 and p = 0.003, respectively) (Fig. 1) . There was no statistically significant difference in EDN and histamine levels between the asthma groups at both time points. No significant variation in EDN and histamine levels between 04:00 and 16:00 hours was found in the three groups. In contrast to EDN, most ECP levels were less than the detection level of 0.1 ng/ml and were therefore not suitable to detect differences between the time points among the various groups.
Eicosanoid levels in BAL fluid are shown in Fig.  2 . Because of the limited recovery of BAL fluid, eicosanoid levels could not be assessed in two subjects with asthma, one from group 2 and one from group 3. Significantly higher levels of PGD 2 were found in group 3 as compared with the other groups at both time points (p -< 0.04). Furthermore, TxB a levels in group 3 were significantly higher as compared with group 2 at both time points (p = 0.04), but this did not reach significance as compared with the control group. Increased levels of leukotriene C4 were found in group 3 at 04:00 hours as compared with the other groups, reaching significance with the control group (p = 0.03). No significant differences in PGF2~ and 6kPGFa~ levels were observed among the various groups. No significant variations in eicosanoid levels between 04:00 and 16:00 hours within the three groups were found.
Peripheral blood analysis
Total leukocyte counts (Table III) did not show a statistically significant difference between normal subjects, all subjects with asthma, or the asthma subgroups at 16:00 and 04:00 hours. Furthermore, there were no variations between 04:00 and 16:00 hours in the three groups.
Eosinophil numbers in PB were significantly higher in all subjects with asthma as compared with the control subjects at 16:00 hours and 04:00 hours (p -0.01), but there was no significant difference between the two asthma groups. Mean total cosinophil counts were increased in all groups at 04:00 hours compared with the 16:00 hour values. This reached significance in group 2 (p = 0.05).
Mean serum ECP level at 16:00 hours were not significantly different between groups 1 and 2, whereas this level was significantly higher in group 3 (p -< 0.03). At 04:00 hours levels in both asthma groups were significantly higher than in the control group (p -0.01), whereas no significant difference was found between the two asthma groups. Mean serum ECP was significantly increased at night in group 2 (p = 0.02) but not in the other groups.
Correlations with circadian PEF variation in subjects with asthma Bronchoalveolar lavage. Eosinophil and EG2 + cell numbers, mast cells, histamine levels, and other eicosanoid levels in the BAL fluid at 16:00 and 04:00 hours and changes between 04:00 and 16:00 hours were not significantly correlated with the circadian PEF variation in subjects with asthma, although a trend was found for higher PGD 2 levels at 16:00 hours and for higher EDN levels at 04:00 hours with a bigger circadian PEF (Fig. 3) . Total eosinophil numbers at 16:00 and 04:00 hours, and variations between 04:00 and 16:00 hours, were not significantly correlated with the circadian PEF variation.
DISCUSSION
We investigated the presence of inflammatory cell numbers and their activation products in BAL fluid and PB and determined their relationship with the occurrence of increased NAN in asthma, as assessed by measurement of the circadian PEF variation. Overall, higher eosinophil numbers and levels of inflammatory cell activation products were found in BAL fluid and PB from subjects with asthma in comparison with control subjects. However, in subjects with asthma with increased circadian PEF rhythm, no specific circadian change in inflammatory cells and the investigated mediators occurred. Most activation parameters at 16:00 and 04:00 hours did not differentiate this group from subjects with asthma without increased NAN. Interestingly, a number of eicosanoid levels in BAL fluid (PGD 2 and TxB2) and serum ECP levels were significantly higher in daytime in subjects with asthma, with increased circadian PEF variation as compared with those without increased circadian PEF variation. A significant cx~rrelation was found between serum ECP and circadian PEF variation in subjects with asthma. In addition, a trend was observed toward a correlation between 16:00 hours BAL PGD 2 levels and circadian PEF variation in subjects with asthma, but no correlation between the TxB 2 levels and the circadian PEF variation existed.
The results together suggest that increased NAN is more lil¢ely to occur in subjects with asthma with higher serum ECP and BAL PGD 2 levels. So far, contradictory results have been reported on the recruitment of leukocytes to the airways at night in nocturnal asthma. Martin et al. 3 demonstrated significant increases in numbers of eosinophils and lymphocytes in BAL fluid in association with increases in total white blood cell counts and neutrophil counts. In contrast, Jarjour et al. 4 did not find changes in BAL cell count in their subjects with nocturnal asthma, which corresponds with our findings. A comparison of patient characteristics of these two studies and ours shows that the subjects with nocturnal asthma in the study of Martin et al. generally had more severe asthma, with lower mean FEV 1 values and higher circadian PEF variations at home. It is therefore possible that only in severe NAN an association can be found with pronounced infiltration of inflammatory cells into the airways, as recovered by BAL fluid. Furthermore, in both of the other studies most of the subjects; used theophylline at the time of investigation, whereas our subjects did not use theophylline, and maintenance therapy was withheld from 4 weeks before the start of the study. Although Martin et al. reported that the mean serum theophylline concentrations at 16:00 and 04:00 hours did not differ, it is not clear whether individual differences in serum concentrations were observed. Changes in theophylline levels are known to modulate PB eosinophil numbers, 25 and we do not exclude the possibility that this may have affected airway leukocyte traffic in their study as well.
Contradictory results have also been reported on variations of PB eosinophil numbers and their activity between 04:00 and 16:00 hours in subjects with nocturnal asthma. Because the eosinophil shows a circadian chronobiologic rhythm with the highest value at night around 2:00 AM in normal subjects, 9 equal or increased numbers are likely to be found at night, depending on the time point of investigation. Eosinophil numbers in subjects with nocturnal asthma were reported to be either normaP and increased 5, 6 at 4:00 AM, or decreased. 7 In our study PB eosinophil numbers increased at night, without a difference between the three groups, whereas no variation in ECP levels between 04:00 and 16:00 hours was found in the group with increased circadian PEF variation. Fitzpatrick et al. 7 reported decreased eosinophil counts, together with reduced serum ECP levels during the night and suggested these findings to be compatible with the involvement of a late asthmatic reaction in the pathogenesis of nocturnal asthma, although it cannot be excluded that the use of inhaled and oral corticosteroids in the latter study may have affected the results. 6 Interestingly, subjects with asthma with increased circadian PEF variation could be distinguished from subjects with asthma without increased circadian PEF variation by significantly higher levels of PGD 2 in BAL and ECP in serum at 16:00 hours, suggesting that increased nocturnal airway obstruction in subjects with asthma occurs in those subjects with a preexisting more severe degree of inflammation. PGD2 is the major pros- tanoid release product of mast cells, although other cells in the airways such as alveolar macrophages and eosinophils can synthesize PGD 2 as well. 26 Indirect evidence of a role for mast cell activation in nocturnal asthma has been suggested by findings that subjects with asthma with increased NAN showed a higher airway hyperresponsiveness to adenosine 5'-monophosphate, 1 which exerts its airway constrictive effect mainly by mast cell activation. On adenosine 5'-monophosphate provocation, PGD 2 levels in the BAL fluid have been reported to be increased. 2v Inhalation of a noncontractile dose of PGD 2 has been shown to potentiate airway hyperresponsiveness to methacholine and histamine. 2s Therefore release of PGD 2 may play an important role in the increased airway hyperresponsiveness at night, underlying increased NAN in asthma. Increased serum ECP levels in subjects with asthma with increased NAN were not accompanied by increased eosinophil activation in BAL fluid in our study. It is possible that measurement of eosinophil activation parameters in BAL fluid does not fully reflect eosinophil activation in the airways or only at a more severe stage of airway inflammation. Studies on biopsy specimens obtained from the bronchial wall may reveal additional information about the involvement of eosinophil activation in increased NAN in asthma.
In contrast to the observed circadian fluctuations in PB samples, we did not find evidence for circadian fluctuations in cell number and mediators in the BAL fluid. In healthy subjects the various PB cell types show different circadian rhythms, resulting in higher numbers of circulating lymphocytes and eosinophils and lower numbers of neutrophils during the night. 9 These fluctuations were not found in the BAL cell numbers. BAL lymphocyte numbers did not change at night, whereas eosinophil numbers increased together with the neutrophil numbers in the control group and the asthma group without circadian PEF rhythm. However, we did not observe these changes in the asthma group with increased circadian PEF rhythm. Possibly these cells are entrapped at night in increased numbers in the airway mucosa in subjects with asthma with increased NAN. This assumption needs further investigation.
In conclusion, we found that increased NAN in subjects with asthma is on the whole not associated with a circadian fluctuation in cell number and inflammatory mediators in PB and BAL fluid. In general, higher numbers of eosinophils and levels of cell activation products are found in BAL fluid and PB from subjects with asthma as compared with control subjects. However, in subjects with asthma with increased nocturnal airways obstruction most activation parameters did not differentiate them from subjects with asthma without nocturnal airways obstruction. Interestingly, significantly higher levels of ECP in serum and PGD 2 in BAL fluid were present in subjects with asthma with increased nocturnal airways obstruction. These findings suggest that increased NAN occurs in subjects with asthma with ongoing increased nonspecific cellular activation during the day.
